Strategy to focus on core health markets in content and clinical decision support solutions globally.
Wolters Kluwer, a market leader in the professional health content and clinical decision support market, today announced a plan to divest its pharma business. The company is well-positioned to benefit from healthcare reform trends globally to support the Health division’s growth strategy.
“The planned divestment of the pharma business will focus our Health division on taking full advantage of our leading positions in professional information and clinical decision support solutions, one of the fastest growing areas of Health, to deliver enhanced value to our stakeholders,” said Nancy McKinstry, CEO and Chairman of the Executive Board of Wolters Kluwer.
The pharma business, with leading brands Source and Adis, provides marketing and publications services, business intelligence products, and advanced analytical tools and services to support life sciences professionals from discovery through development and distribution.
“The pharma business delivers great value to our pharmaceutical, biotech and medical device customers globally,” said Bob Becker, President & CEO of Wolters Kluwer Health & Pharma Solutions. “Moving forward, we are excited about continued opportunities to deliver value to global customers through our portfolio of leading brands in content and clinical decision support, which are well-positioned to benefit from healthcare reform trends globally to support the division’s growth strategy.”
Wolters Kluwer Health & Pharma Solutions is a global provider of information, business intelligence and point-of-care solutions for the healthcare industry, with leading brands including Lippincott Williams & Wilkins, Ovid®, Pharmacy OneSource®, Lexicomp and UpToDate®, among others. Its customers include professionals, students, institutions and organizations across the globe. Products and services include industry-leading textbooks and journals, electronic drug data and clinical information, electronic medical, scientific and academic research solutions, clinical decision support solutions and evidence-based content that is easily accessible at the point of care.
The company expects the planned divestiture to close around or shortly after the end of the year. Lazard Middle Market and William Blair & Company are acting as financial advisors to Wolters Kluwer Health & Pharma Solutions for the planned divestiture.
